Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac
Primary Purpose
Tuberculosis
Status
Recruiting
Phase
Phase 3
Locations
Russian Federation
Study Type
Interventional
Intervention
GamTBvac
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Tuberculosis
Eligibility Criteria
Inclusion Criteria:
- Healthy male and female volunteers aged 18-45 years (inclusive);
- Volunteers from population groups with a high incidence of tuberculosis (more than 30 people per 100 thousand population);
- Absence of active tuberculosis, confirmed by chest x-ray;
- Body mass index 18.5 - 30 kg / m2 (inclusive) according to Quetelet's weight and height index;
- Signed informed consent to participate in the study in accordance with the current legislation;
- Previous bacille Calmette Guerin (BCG) vaccination according to medical history or confirmed by the presence of a scar;
- Absence of markers of the immune response to mycobacterial proteins ESAT6 and CFP10, which characterize the probable contact with M. tuberculosis prior to the start of the study confirmed by the tuberculosis skin test;
- Negative pregnancy test in female volunteers with preserved reproductive potential at screening and on the day of the first vaccination;
- Consent of male and female participants with preserved reproductive potential to observe an adequate method of contraception (double barrier method: male or female condom and combined hormonal contraceptive (oral, vaginal and transdermal forms can be used) during the entire period of vaccination and 1 month after completion of vaccination Exception: surgically sterile (more than 6 months) or postmenopausal (more than 12 months);
- Consent of male participants not to participate in sperm donation during the entire period of vaccination and 1 month after completion of vaccination.
Non-inclusion criteria:
- Positive test results for HIV-1/2 antibodies, HBsAg or hepatitis C antibodies at screening;
- History of tuberculosis (any localization);
- History of chronic respiratory disease, including idiopathic pulmonary fibrosis (IPF), bronchial asthma, chronic obstructive pulmonary disease (COPD), or pulmonary hypertension.
- Clinically significant ECG abnormalities at screening;
- Aggravated allergic history;
- Hypersensitivity to any component of the study drug or placebo; a history of drug intolerance;
- History or presence of any disease or drug intake that, in the opinion of the investigator, may interfere with the assessment of the safety or efficacy of the vaccine.
- History or presence of any possible immunodeficiency state according to physical and laboratory examination;
- History of autoimmune disease (including systemic lupus erythematosus, type 1 diabetes, etc.);
- Regular intake (lasting more than 2 weeks) of immunosuppressants or other immunomodulatory drugs less than 6 months before the start of the study (except the inhaled or topical forms of corticosteroids);
- The use of immunoglobulin or blood products within 3 months before the start of the study or their planned appointment during the study;
- Intake of antibacterial drugs within 14 days before vaccination (oral) and within 28 days before vaccination (parenteral);
- Pregnancy, lactation, refusal to use barrier methods of contraception, woman's participation in an egg donation program;
- Inability of the volunteer to understand the objectives, goals, research design, inability to comply with the prescribed protocol and schedule of visits and procedures;
- Participation in clinical trials of medicinal products less than 3 months before the start of this study, or planned participation in another clinical trial;
- Previous receipt of the GamTBvac vaccine and / or participation in clinical trials of any experimental anti-tuberculosis vaccines;
- Any vaccination or planned vaccination less than a month before the first vaccination in this study or within a month after each vaccination in this study.
- Anamnestic information about alcoholism, drug addiction, drug abuse;
- Positive result of urine analysis for narcotic and psychotropic drugs;
- Positive test for ethanol (exhaled air).
Exclusion Criteria:
Participation of a volunteer in the study may be terminated for the following reasons:
- Development of primary tuberculosis of the respiratory system;
- The researcher decided that the volunteer should be excluded in the interests of the volunteer himself;
- The volunteer has a serious adverse event related to the study vaccine;
- Failure to comply with the rules of participation in the study;
- The participant refuses to cooperate or is undisciplined;
- The participant was included in violation of the inclusion / non-inclusion criteria of the protocol;
- Development of any other significant adverse events;
- Deterioration of the volunteer's health.
Sites / Locations
- City hospital #40Recruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Vaccine Group
Placebo group
Arm Description
3590 volunteers who will receive 1 dose (0.5 ml) of the vaccine GamTBvac administered twice with an 8-week interval between administrations.
3590 volunteers who will receive 1 dose (0.5 ml) of the placebo administered subcutaneously twice with an 8-week interval between administrations.
Outcomes
Primary Outcome Measures
Preventive efficacy (Ep)
Preventive efficacy calculated as Ep=(1-RR)∗100%, where RR is the relative risk of developing pulmonary tuberculosis in the vaccine group compared to placebo
Secondary Outcome Measures
Full Information
NCT ID
NCT04975737
First Posted
July 9, 2021
Last Updated
November 25, 2022
Sponsor
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
1. Study Identification
Unique Protocol Identification Number
NCT04975737
Brief Title
Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac
Official Title
Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac in Preventing the Development of Respiratory Tuberculosis Not Associated With HIV Infection in Volunteers Aged 18-45 Years
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 20, 2022 (Actual)
Primary Completion Date
November 2025 (Anticipated)
Study Completion Date
November 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This is a multicenter, double-blind, randomized (in 1:1 ratio) placebo-controlled study to assess the safety and protective efficacy of the subunit recombinant tuberculosis vaccine GamTBvac against the development of respiratory tuberculosis not associated with HIV infection in volunteers aged 18-45 years.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tuberculosis
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
7180 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Vaccine Group
Arm Type
Experimental
Arm Description
3590 volunteers who will receive 1 dose (0.5 ml) of the vaccine GamTBvac administered twice with an 8-week interval between administrations.
Arm Title
Placebo group
Arm Type
Placebo Comparator
Arm Description
3590 volunteers who will receive 1 dose (0.5 ml) of the placebo administered subcutaneously twice with an 8-week interval between administrations.
Intervention Type
Biological
Intervention Name(s)
GamTBvac
Intervention Description
The subunit recombinant tuberculosis vaccine GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose)
Intervention Type
Biological
Intervention Name(s)
Placebo
Intervention Description
Placebo for subcutaneous administration
Primary Outcome Measure Information:
Title
Preventive efficacy (Ep)
Description
Preventive efficacy calculated as Ep=(1-RR)∗100%, where RR is the relative risk of developing pulmonary tuberculosis in the vaccine group compared to placebo
Time Frame
24 months after vaccination
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male and female volunteers aged 18-45 years (inclusive);
Volunteers from population groups with a high incidence of tuberculosis (more than 30 people per 100 thousand population);
Absence of active tuberculosis, confirmed by chest x-ray or computed tomography;
Body mass index 18.5 - 30 kg / m2 (inclusive) according to Quetelet's weight and height index;
Signed informed consent to participate in the study in accordance with the current legislation;
Previous bacille Calmette Guerin (BCG) vaccination according to medical history or confirmed by the presence of a scar;
Absence of markers of the immune response to mycobacterial proteins ESAT6 and CFP10, which characterize the probable contact with M. tuberculosis prior to the start of the study confirmed by the tuberculosis skin test;
Negative pregnancy test in female volunteers with preserved reproductive potential at screening and on the day of the first vaccination;
Consent of male and female participants with preserved reproductive potential to observe an adequate method of contraception (double barrier method: male or female condom and combined hormonal contraceptive (oral, vaginal and transdermal forms can be used) or using a condom or diaphragm with spermicide during the entire period of vaccination and 1 month after completion of vaccination Exception: surgically sterile (more than 6 months) or postmenopausal (more than 12 months);
Consent of male participants not to participate in sperm donation during the entire period of vaccination and 1 month after completion of vaccination.
Non-inclusion criteria:
Positive test results for HIV-1/2 antibodies, HBsAg or hepatitis C antibodies at screening;
History of extrapulmonary tuberculosis;
History of chronic non-infectious respiratory disease, including idiopathic pulmonary fibrosis (IPF), bronchial asthma, chronic obstructive pulmonary disease (COPD), or pulmonary hypertension.
Clinically significant ECG abnormalities at screening;
Aggravated allergic history (bronchial asthma, history of anaphylaxis reactions);
Hypersensitivity to any component of the study drug or placebo; a history of drug intolerance;
History or presence of any disease or drug intake that, in the opinion of the investigator, may interfere with the assessment of the safety or efficacy of the vaccine.
History or presence of any possible immunodeficiency state according to physical and laboratory examination;
History of autoimmune disease (including systemic lupus erythematosus, type 1 diabetes, etc.);
Regular intake (lasting more than 2 weeks) of immunosuppressants or other immunomodulatory drugs less than 6 months before the start of the study (except the inhaled or topical forms of corticosteroids);
The use of immunoglobulin or blood products within 3 months before the start of the study or their planned appointment during the study;
Intake of antibacterial drugs within 14 days before vaccination (oral) and within 28 days before vaccination (parenteral);
Pregnancy, lactation, refusal to use double barrier method of contraception, woman's participation in an egg donation program;
Inability of the volunteer to understand the objectives, goals, research design, inability to comply with the prescribed protocol and schedule of visits and procedures;
Participation in clinical trials of medicinal products less than 3 months before the start of this study, or planned participation in another clinical trial;
Previous receipt of the GamTBvac vaccine and / or participation in clinical trials of any experimental anti-tuberculosis vaccines;
Any vaccination or planned vaccination less than a month before the first vaccination in this study or within a month after each vaccination in this study.
Anamnestic information about alcoholism, drug addiction, drug abuse;
Positive result of urine analysis for narcotic and psychotropic drugs;
Positive test for ethanol (exhaled air or using saliva test strips).
Exclusion Criteria:
Participation of a volunteer in the study may be terminated for the following reasons:
Development of primary tuberculosis of the respiratory system;
The researcher decided that the volunteer should be excluded in the interests of the volunteer himself;
The volunteer has a serious adverse event related to the study vaccine;
Failure to comply with the rules of participation in the study;
The participant refuses to cooperate or is undisciplined;
The participant was included in violation of the inclusion / non-inclusion criteria of the protocol;
Development of any other significant adverse events;
Deterioration of the volunteer's health.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maria Semashko
Phone
+7 (499) 193-30-01
Email
info@gamaleya.org
Facility Information:
Facility Name
City hospital #40
City
Saint Petersburg
ZIP/Postal Code
197706
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alina Agafyina, PhD
Phone
+7 812 437 35 22
Email
a.agafina@mail.ru
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac
We'll reach out to this number within 24 hrs